Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 7/20 | 0.48 |
| ▸ | ERBB3 | P21860 | 4/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690919 | 0.89 | NPC1 (0.55) | NPC1MKNK1EGFRERBB3MAPK1 | |
| SCHEMBL20040802 | 0.86 | NPC1 (0.52) | NPC1MKNK1EGFRERBB3SCN9A | |
| SCHEMBL22328022 | 0.83 | NPC1 (0.64) | NPC1MKNK1EGFRERBB3SCN9A | |
| SCHEMBL2283204 | 0.82 | NPC1 (0.68) | NPC1MKNK1EGFRERBB3SCN9A | |
| Hydrochloric Acid SCHEMBL2176150 | 0.81 | NPC1 (0.66) | NPC1MKNK1EGFRERBB3SCN9A | |
| SCHEMBL15542527 | 0.80 | NPC1 (0.47) | NPC1MKNK1EGFRERBB3TNNI3K | |
| SCHEMBL2279563 | 0.79 | MEN1 (0.56) | NPC1MKNK1EGFRERBB3MAPK1 | |
| SCHEMBL3952295 | 0.78 | EGFR (0.66) | NPC1MKNK1EGFRERBB3TNNI3K | |
| SCHEMBL14322670 | 0.78 | TNNI3K (0.57) | NPC1MKNK1EGFRTNNI3K | |
| Hydrochloric Acid SCHEMBL2173883 | 0.77 | EGFR (0.64) | NPC1MKNK1EGFRERBB3TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| EP-2523559-A1 | COMPOUNDS AND METHODS | GlaxoSmithKline LLC (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | NPC1 383/4885MKNK1 4004/4885EGFR 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.